Reported by PR Newswire published-Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD toEvaluate DR30303 in Combination with KEYTRUDAR® (pembrolizumab) in Patients with Gastric or Gastroesophageal Junction Cancer